wfmz.com | Your Life, Your World, Your NEWS
WFMZ-TV 69 News serves the Lehigh Valley, Berks County, and Philadelphia regions with news and family programming
Related Articles
U.S. FDA declines to approve Eli Lilly’s drug to treat eczema
The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings…
Protecting children from poor air quality
3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy…
FDA Reviewers Say OTC Decongestant Doesn’t Work
But they acknowledge that taking the only shelf-accessible product off the market raises issues
Nestlé offloads peanut allergy therapy Palforzia to Stallergenes Greer
Nestlé announced Monday the divestment of its peanut allergy treatment business Palforzia (peanut allergen powder-dnfp) to Stallergenes Greer for an undisclosed sum. Nestlé kicked off…
AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study | BioSpace
Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.
St. Luke’s orders $30M of CT equipment with artificial intelligence
The 21 CT systems ordered from GE HealthCare will provide faster scans and sharper images, with the potential to reduce radiation doses, a statement says.
‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients
For patients who have undiagnosed cancer, a months-long delay due to new prior authorization requirements for colonoscopies could be disastrous.
Dupilumab not linked to short-term cancer development in patients with atopic dermatitis
Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published…
FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome
The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.